Scaling of Cmin [Regulatives / Guidelines]

posted by VStus – Poland, 2017-02-03 16:37 (3431 d 22:59 ago) – Posting: # 17008
Views: 14,139

Dear zizou,

Thank you very much for the feedback!

I've tried 4 periods instead of 2 and got even higher variation, which seems to be an overestimation:
summary(data)
##       subj    seq     prd    drug   rep          AUC       
##  1      : 2   RT:20   1:10   R:40   R1:20   Min.   : 439.0 
##  2      : 2   TR:20   2:10          R2:20   1st Qu.: 656.5 
##  3      : 2           3:10                  Median : 781.5 
##  4      : 2           4:10                  Mean   : 795.6 
##  5      : 2                                 3rd Qu.: 929.8 
##  6      : 2                                 Max.   :1297.0 
##  (Other):28
anovadata <- lm(log(AUC) ~ seq + subj:seq + rep + prd, data=data, na.action=na.exclude)
anova(anovadata)
## Analysis of Variance Table
##
## Response: log(AUC)
##           Df  Sum Sq  Mean Sq F value  Pr(>F) 
## seq        1 0.20989 0.209885  6.2514 0.02230 *
## rep        1 0.00507 0.005067  0.1509 0.70222 
## prd        1 0.00169 0.001689  0.0503 0.82505 
## seq:subj  18 1.55131 0.086184  2.5670 0.02631 *
## Residuals 18 0.60433 0.033574                 
## ---
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
100*sqrt(exp(0.033574)-1)
## [1] 18.47812


Removing replication from the model does not change residual MS :)

Regards, VStus

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
359 visitors (0 registered, 359 guests [including 11 identified bots]).
Forum time: 16:36 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5